GlycoMimetics is proud
National Sickle Cell
in September 2020
GlycoMimetics is evaluating its drug candidate
in adults with acute myeloid leukemia.
Our pivotal trial for uproleselan is being conducted under the auspices of the FDA’s Breakthrough Therapy designation.
We are applying our expertise in carbohydrate biology and chemistry to design high-potency
inhibitors of galectin-3.
These therapies could be instrumental in treating fibrosis and various forms of cancer
Our expertise in glycosciences distinguishes our development of potentially groundbreaking therapies to treat serious oncology, immunology, and inflammatory conditions.